Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(6R)-N10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
(6R)-tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
10-formyl-5,8-dideazafolate + beta-glycinamide ribonucleotide
5,8-dideazafolate + N-formyl beta-glycinamide ribonucleotide
-
-
-
-
?
10-formyl-5,8-dideazafolate + carbocyclic beta-glycinamide ribonucleotide
5,8-dideazafolate + N-formyl carbocyclic beta-glycinamide ribonucleotide
10-formyl-5,8-dideazafolate + N1-(5-phospho-D-ribosyl)glycinamide
?
-
-
-
-
?
10-formyltetrahydrofolate + (alpha,beta)-glycinamide ribonucleotide
tetrahydrofolate + formylglycinamide ribonucleotide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
10-formyltetrahydrofolate + beta-5-phospho-D-ribosylglycinamide
tetrahydrofolate + beta-5'-phosphoribosyl-N-formylglycinamide
10-formyltetrahydrofolate + carbocyclic beta-glycinamide ribonucleotide
tetrahydrofolate + formyl glycinamide ribonucleotide
10-formyltetrahydrofolate + glycinamide ribonucleotide
tetrahydrofolate + formylglycinamide ribonucleotide
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide
tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide
10-formyltetrahydrofolate + N5-hydroxyornithine
tetrahydrofolate + N5-formyl-N5-hydroxyornithine
-
-
-
-
?
10-formyltetrahydrofolate + O-phosphonate carbocyclic glycinamide ribonucleotide
tetrahydrofolate + O-phosphonate-ribosyl-N-formylglycinamide
-
-
-
-
?
5'-phosphoribosylglycinamide + 10-formyl-5,8-dideazafolate
5'-phosphoribosyl-N-formylglycinamide + 5,8-dideazafolate
-
-
-
-
r
acetate + ATP
acetyl phosphate + ADP
beta-glycinamide ribonucleotide + 10-formyltetrahydrofolate
?
-
-
-
-
?
beta-glycinamide ribonucleotide + ATP + formate
beta-formylglycinamide ribonucleotide + ADP
-
assay at 25°C
-
-
?
formate + ATP + beta-glycinamide ribonucleotide
beta-formylglycinamide ribonucleotide + ADP
inosinic acid + glycinamide ribotide + H2O
5-amino-4-imidazolecarboxamide ribotide + formylglycinamide ribotide
-
-
-
-
?
N10-formyl-5-deazafolate + glycinamide ribonucleotide
formylglycinamide ribonucleotide + 5-deazafolate
-
-
-
-
?
N10-formyl-8-deazafolate + glycinamide ribonucleotide
formylglycinamide ribonucleotide + 8-deazafolate
-
-
-
-
?
N10-formyldideazafolate + 5-phospho-D-ribosylglycinamide
dideazafolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
N10-formylfolate + glycinamide ribonucleotide
folate + formylglycinamide ribonucleotide
-
-
-
-
?
N5,N10-anhydroformyl-5,6,7,8tetrahydrofolic acid + 2-amino-N-ribosylacetamide 5'-phosphate + H2O
formylglycinamide ribotide + tetrahydrofolic acid + 2-formamido-N-ribosylacetamide 5'-phosphate
-
-
-
-
ir
N5,N10-anhydroformyltetrahydrofolate + glycinamide ribotide + H2O
N10-formyltetrahydrofolate + formylglycinamide ribotide
N5,N10-anhydroformyltetrahydrofolic acid + glycinamide ribonucleotide
formylglycinamide ribonucleotide + ?
-
-
-
-
?
additional information
?
-
(6R)-N10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
(6R)-tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
(6R)-N10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
(6R)-tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
(6R)-N10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
(6R)-tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyl-5,8-dideazafolate + carbocyclic beta-glycinamide ribonucleotide
5,8-dideazafolate + N-formyl carbocyclic beta-glycinamide ribonucleotide
-
-
-
?
10-formyl-5,8-dideazafolate + carbocyclic beta-glycinamide ribonucleotide
5,8-dideazafolate + N-formyl carbocyclic beta-glycinamide ribonucleotide
-
-
-
-
?
10-formyl-5,8-dideazafolate + carbocyclic beta-glycinamide ribonucleotide
5,8-dideazafolate + N-formyl carbocyclic beta-glycinamide ribonucleotide
-
-
-
-
?
10-formyl-5,8-dideazafolate + carbocyclic beta-glycinamide ribonucleotide
5,8-dideazafolate + N-formyl carbocyclic beta-glycinamide ribonucleotide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
485714, 485715, 485718, 485719, 485720, 485727, 485728, 485729, 485730, 485731, 485732, 485733, 485734, 485735, 485736, 485738, 485740, 485741 -
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
r
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
third step in de novo purine biosynthetic pathway
-
-
r
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
485715, 485718, 485719, 485720, 485728, 485729, 485731, 485734, 485735, 485738, 485740, 485741 -
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
in uricotelic organisms such as birds, the major role of this active pathway is elimination of waste nitrogen
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
1312, 172166, 485718, 485721, 485724, 485725, 485728, 485729, 485731, 485734, 485735, 485738 -
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
transformylation reaction of purine biosynthesis
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
in ureotelic animals such as mammals the role of the far less active pathway is to provide purine nucleotides for further anabolic sequences
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
third step in de novo purine biosynthetic pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
carries out the second, third and fifth sequential reactions of de novo purine synthesis pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
involved in pyoverdine synthesis
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + beta-5-phospho-D-ribosylglycinamide
tetrahydrofolate + beta-5'-phosphoribosyl-N-formylglycinamide
-
-
-
?
10-formyltetrahydrofolate + beta-5-phospho-D-ribosylglycinamide
tetrahydrofolate + beta-5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + beta-5-phospho-D-ribosylglycinamide
tetrahydrofolate + beta-5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + carbocyclic beta-glycinamide ribonucleotide
tetrahydrofolate + formyl glycinamide ribonucleotide
-
-
-
-
?
10-formyltetrahydrofolate + carbocyclic beta-glycinamide ribonucleotide
tetrahydrofolate + formyl glycinamide ribonucleotide
-
-
-
-
?
10-formyltetrahydrofolate + carbocyclic beta-glycinamide ribonucleotide
tetrahydrofolate + formyl glycinamide ribonucleotide
-
-
-
-
?
10-formyltetrahydrofolate + glycinamide ribonucleotide
tetrahydrofolate + formylglycinamide ribonucleotide
-
-
-
-
?
10-formyltetrahydrofolate + glycinamide ribonucleotide
tetrahydrofolate + formylglycinamide ribonucleotide
-
-
-
-
?
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide
tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide
-
-
-
-
?
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide
tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide
-
-
-
?
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide
tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide
-
-
-
-
?
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide
tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide
-
-
-
-
?
acetate + ATP
acetyl phosphate + ADP
-
novel non-folate glycinamide ribonucleotide transformylase purT gene product, no significant homology to known EC 2.1.2.2 but significant homology to the purK protein also involved in purine biosynthesis
-
-
?
acetate + ATP
acetyl phosphate + ADP
-
novel non-folate glycinamide ribonucleotide transformylase purT gene product, no significant homology to known EC 2.1.2.2 but significant homology to the purK protein also involved in purine biosynthesis
-
-
?
formate + ATP + beta-glycinamide ribonucleotide
beta-formylglycinamide ribonucleotide + ADP
-
novel non-folate glycinamide ribonucleotide transformylase purT gene product, no significant homology to known EC2.1.2.2 but significant homology to the purK protein also involved in purine biosynthesis
-
-
?
formate + ATP + beta-glycinamide ribonucleotide
beta-formylglycinamide ribonucleotide + ADP
-
novel non-folate glycinamide ribonucleotide transformylase purT gene product, no significant homology to known EC2.1.2.2 but significant homology to the purK protein also involved in purine biosynthesis
-
-
?
N5,N10-anhydroformyltetrahydrofolate + glycinamide ribotide + H2O
N10-formyltetrahydrofolate + formylglycinamide ribotide
-
-
-
-
?
N5,N10-anhydroformyltetrahydrofolate + glycinamide ribotide + H2O
N10-formyltetrahydrofolate + formylglycinamide ribotide
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
monofunctional enzyme
-
-
?
additional information
?
-
-
monofunctional enzyme
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
monofunctional enzyme
-
-
?
additional information
?
-
-
monofunctional enzyme
-
-
?
additional information
?
-
-
10-formyl-dideazaformate, 5-formyltetrahydroformate, formylaminoimidazolecarboxamide ribonucleotide, formylmethionine, formiminoglutamate, GTP, CTP, TTP, ITP and ZTP are no substrates for the purT GAR transformylase
-
-
?
additional information
?
-
-
purT GAR transformylase is the first unknown de novo purine biosynthetic enzyme to be discovered in the last 30 years and represents another step forward in understanding cellular control of purine levels
-
-
?
additional information
?
-
-
10-formyl-dideazaformate, 5-formyltetrahydroformate, formylaminoimidazolecarboxamide ribonucleotide, formylmethionine, formiminoglutamate, GTP, CTP, TTP, ITP and ZTP are no substrates for the purT GAR transformylase
-
-
?
additional information
?
-
-
purT GAR transformylase is the first unknown de novo purine biosynthetic enzyme to be discovered in the last 30 years and represents another step forward in understanding cellular control of purine levels
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
reaction does not occur if glycine, glycinamide or glycinamide riboside is substituted for glycinamide ribotide
-
-
?
additional information
?
-
-
glycinamide ribonucleotide nucleoside is no substrate
-
-
?
additional information
?
-
-
trifunctional enzyme, GAR synthetase, aminoimidazole ribonucleotide synthetase and GAR transformylase
-
-
?
additional information
?
-
-
trifunctional enzyme, GAR synthetase, aminoimidazole ribonucleotide synthetase and GAR transformylase
-
-
?
additional information
?
-
-
trifunctional enzyme, GAR synthetase, aminoimidazole ribonucleotide synthetase and GAR transformylase
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
additional information
?
-
-
GAR transformylase activity copurifies with 5,10-methylene-, 5,10-methenyl, and 10-formyl-H4folate sythetase (combined) trifunctional enzyme, EC 6.3.4.3, EC 1.5.1.5 and EC 3.5.4.9
-
-
?
additional information
?
-
-
purified along with 10-formyltetrahydrofolate synthetase
-
-
?
additional information
?
-
-
uses both diastereomers of 5,10-methenyltetrahydrofolate, (+)-L-diastereomer is used 120 times faster than the (-)-L-diastereomer
-
-
?
additional information
?
-
-
trifunctional enzyme, GAR synthetase, aminoimidazole ribonucleotide synthetase and GAR transformylase
-
-
?
additional information
?
-
-
trifunctional enzyme, GAR synthetase, aminoimidazole ribonucleotide synthetase and GAR transformylase
-
-
?
additional information
?
-
-
trifunctional enzyme, GAR synthetase, aminoimidazole ribonucleotide synthetase and GAR transformylase
-
-
?
additional information
?
-
-
alpha-glycinamide ribonucleotide and glycinamide ribonucleotide nucleoside are neither substrates for no inhibitors
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
additional information
?
-
-
trifunctional enzyme, GAR synthetase, aminoimidazole ribonucleotide synthetase and GAR transformylase
-
-
?
additional information
?
-
-
trifunctional enzyme, GAR synthetase, aminoimidazole ribonucleotide synthetase and GAR transformylase
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
additional information
?
-
-
trifunctional enzyme, GAR synthetase, aminoimidazole ribonucleotide synthetase and GAR transformylase
-
-
?
additional information
?
-
-
3 activities in a multifunctional protein, posessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotidetransformylase and aminoimidazole ribonucleotide synthetase
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
10-formyltetrahydrofolate + glycinamide ribonucleotide
tetrahydrofolate + formylglycinamide ribonucleotide
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide
tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
third step in de novo purine biosynthetic pathway
-
-
r
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
485715, 485718, 485719, 485720, 485728, 485729, 485731, 485734, 485735, 485738, 485740, 485741 -
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
in uricotelic organisms such as birds, the major role of this active pathway is elimination of waste nitrogen
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
1312, 172166, 485718, 485721, 485724, 485725, 485728, 485729, 485731, 485734, 485735, 485738 -
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
transformylation reaction of purine biosynthesis
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
in ureotelic animals such as mammals the role of the far less active pathway is to provide purine nucleotides for further anabolic sequences
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
third step in de novo purine biosynthetic pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
essential enzyme in DNA synthesis, third enzyme in de novo purine biosynthesis pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
carries out the second, third and fifth sequential reactions of de novo purine synthesis pathway
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
involved in pyoverdine synthesis
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + 5-phospho-D-ribosylglycinamide
tetrahydrofolate + 5'-phosphoribosyl-N-formylglycinamide
-
-
-
-
?
10-formyltetrahydrofolate + glycinamide ribonucleotide
tetrahydrofolate + formylglycinamide ribonucleotide
-
-
-
-
?
10-formyltetrahydrofolate + glycinamide ribonucleotide
tetrahydrofolate + formylglycinamide ribonucleotide
-
-
-
-
?
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide
tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide
-
-
-
-
?
10-formyltetrahydrofolate + N1-(5-phospho-D-ribosyl)glycinamide
tetrahydrofolate + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide
-
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2S)-2-(((5-(2-((6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]-pyrimidin-6-yl)ethyl)thiophene-2-yl)carbonyl)amino)-pentanedioic acid
LY309887
(2S)-2-(((5-(2-((6S)-2-amino-4-oxo-1,6,7,8-tetrahydropyrimido[5,4-b]-[1,4]thiazin-6-yl)ethyl)thiophene-2-yl)carbonyl)amino)-pentanedioic acid
AG2034
(2S)-2-[[4-[(1RS)-1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid
-
(6R)-5,10-dideazatetrahydrofolate
-
lometrexol
(6R)-dideazatetrahydrofolate diglutamate
(6R)-dideazatetrahydrofolate pentaglutamate
(6R)-dideazatetrahydrofolate tetraglutamate
(6R)-dideazatetrahydrofolate triglutamate
(6S)-dideazatetrahydrofolate
(6S)-N10-formyltetrahydrofolate
-
-
(alpha,beta)-hydroxyacetamide ribonucleotide
-
-
(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid
-
-
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid
-
-
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid
-
-
(S)-2-(4-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl)benzamido)pentanedioic acid
-
(S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid
-
(S)-2-(4-(2-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl)-1,3-dithian-2-yl)benzamido)pentanedioic acid
-
-
(S)-2-(4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl)benzamido)pentanedioic acid
-
(S)-2-(4-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)butyl)benzamido)pentanedioic acid
-
(S)-2-(4-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)pentyl)benzamido)pentanedioic acid
-
(S)-2-(4-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)hexyl)benzamido)pentanedioic acid
-
(S)-2-(5-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-5-yl)propyl)thiophene-2-carboxamido)pentanedioic acid
-
(S)-2-(5-(4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-5-yl)butyl)thiophene-2-carboxamido)pentanedioic acid
-
(S)-2-(5-(5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-5-yl)pentyl)thiophene-2-carboxamido)pentanedioic acid
-
(S)-2-(5-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-5-yl)hexyl)thiophene-2-carboxamido)pentanedioic acid
lometrexol, LMTX
(S)-2-[2-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo [2,3-d]pyrimidin-6-yl)-acetylamino]-acetylamino]-pentanedioic acid
-
-
(S)-2-[3-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo [2,3-d]pyrimidin-6-yl)-acetylamino]-propionylamino]-pentanedioic acid
-
-
(S)-2-[4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo [2,3-d]pyrimidin-6-yl)-acetylamino]-benzoylamino]-pentanedioic acid
-
-
(S)-2-[4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo [2,3-d]pyrimidin-6-yl)-acetylamino]-butyrylamino]-pentanedioic acid
-
-
(S)-2-[5-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo [2,3-d]pyrimidin-6-yl)-acetylamino]-pentanoylamino]-pentanedioic acid
-
-
(S)-2-[6-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo [2,3-d]pyrimidin-6-yl)-acetylamino]-hexanoylamino]-pentanedioic acid
-
-
1-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-acetyl]-piperidine-4-carboxylic acid (pyridin-3-ylmethyl)-amide
-
10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
specifically inhibits recombinant GAR Tfase, inactive against other folate-dependent enzymes, potent inhibitor of tumor cell proliferation
10-Acetyl-5,8-dideazafolate
10-formyl-5,10-dideaza-5,6,7,8-tetrahydrofolic acid
-
10-formyl-5,8-dideazafolic acid hexaglutamate
-
-
10-methanesulfonyl-5-DACTHF
-
-
10-methanesulfonyl-DDACTHF
-
-
10-methylthio-DDACTHF
-
-
10-trifluoroacetyl-DDACTHF
2',3'-dideoxy-2',3'-didehydro-carbocyclic glycinamide ribonucleotide
-
-
2',3'-dideoxy-carbocyclic glycinamide ribonucleotide
-
-
2',5'-furan-dideazatetrahydrofolate
2',5'-thiophene dideazatetrahydrofolate
2,4-diamino-6-(3,4,5-trimethoxyanilino)-methylpyrido[3,2-d]pyrimidine
PY873
2,4-diamino-6-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-quinazoline
PY899
2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-N-[[(pyridin-3-ylmethyl)-carbamoyl]-methyl]-acetamide
-
2-deaminodideazatetrahydrofolate
-
-
3-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-acetylamino]-N-pyridin-3-ylmethyl-propionamide
-
4-([2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-acetylamino]-methyl)-N-pyridin-3-ylmethyl-benzamide
inhibition of thymidylate synthase, as well as glycinamide ribonucleotide formyltransferase and ribonucleotide formyltransferase. Growth inhibition of 4-([2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-acetylamino]-methyl)-N-pyridin-3-ylmethyl-benzamide toward KB cells results in cytotoxicity and G1/G2-phase accumulation, and is partially protected by excess thymidine and adenosine, but is completely reversed in the combination of thymidine and adenosine
4-carbamoyl-2-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid
4-carbamoyl-4-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid
4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-acetylamino]-cyclohexanecarboxylic acid (pyridin-3-ylmethyl)-amide
-
4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-acetylamino]-N-pyridin-3-ylmethyl-benzamide
-
4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-acetylamino]-N-pyridin-3-ylmethyl-butyramide
-
5'-phosphonate carbocyclic glycinamide ribonucleotide
-
-
5,10-dideaza-5,6,7,8-tetrahydrofolate
5,10-dideaza-5,6,7,8-tetrahydrofolic acid
-
-
5,10-dideazafolic acid
-
-
5,10-dideazatetrahydrofolate
5,8-dideazafolate hexaglutamate
-
-
5,8-dideazapteroyl hexaglutamate
-
-
5-((4-carboxy-4-(4-(((2,4-diaminopyrido[3,2-d]pyrimidine-6-yl)methyl)amino)benzamido)butyl)carbamoyl)-isophthalic acid
iDIA
5-deazatetrahydrofolate
-
-
5-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-acetylamino]-pentanoic acid (pyridin-3-ylmethyl)-amide
-
6-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)-acetylamino]-hexanoic acid (pyridin-3-ylmethyl)-amide
-
alpha,beta-hydroxyacetamideribonucleotide
-
-
alpha,beta-N-(hydroxyacetyl)-D-ribofuranosylamine
-
-
beta-thioglycinamide dideazafolate
-
-
dideazatetrahydrofolate
-
-
dideazatetrahydrofolate hexaglutamate
-
-
homo-dideazatetrahydrofolate
-
-
L-(+)-10-formyltetrahydrofolate
-
excellent competitive inhibitor
LY231514
-
antitumor activity may result from simultaneous and multiple inhibition of several key folate-requiring enzymes via its polyglutamated metabolites
LY231514 monoglutamate
-
-
LY231514 pentaglutamate
-
-
N-(4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-L-glutamic acid
-
N-(4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-propyl]benzoyl)-L-glutamic acid
N-(4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-butyl]benzoyl)-L-glutamic acid
N-(4-[5-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-pentyl]benzoyl)-L-glutamic acid
N-(4-[6-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-hexyl]benzoyl)-L-glutamic acid
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamyl-gamma-glutamyl-gamma-glutamylglutamic acid
-
-
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)-gamma-glutamyl-gamma-glutamylglutamic acid
-
-
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid
-
-
N-(5-[N-(3,4-dihydro-2-methyl-4-oxyquinazolin-6-ylmethyl)-N-methyl-amino]-2-thienoyl)-L-glutamic acid
-
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid
-
-
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid
-
-
N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid
-
-
N-([4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]phenyl]carbonyl)glutamic acid
N-([4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]phenyl]carbonyl)glutamic acid
N-([5-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2,3-dihydrothiophen-2-yl]carbonyl)-4-methylideneglutamic acid
-
-
N-([5-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophen-2-yl]carbonyl)-L-glutamic acid
-
N-([5-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophen-2-yl]carbonyl)-L-glutamic acid
-
N-[(5-[2-[(6R)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophen-2-yl)carbonyl]glutamic acid
modeling
N-[(5-[2-[(6R)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl]thiophen-2-yl)carbonyl]glutamic acid
modeling
N-[(5-[2-[(6S)-2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]thiophen-2-yl)carbonyl]glutamic acid
modeling
N-[4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]benzoyl]glutamic acid
binding structure analysis, modeling, overview
N-[4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]benzoyl]glutamic acid
binding structure analysis, modeling, overview
N-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2-fluorobenzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-(2-amino-4-methylquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
-
-
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
N-[4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)propyl]benzoyl]-L-glutamic acid
N-[4-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl]benzoyl]-L-glutamic acid
-
N-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]benzoyl]glutamic acid
-
N-[4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
-
-
N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid
-
effective inhibitor
N-[4-[5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)pentyl]benzoyl]-L-glutamic acid
-
-
N-[4-[6-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1,1,1-trifluoro-2-oxohexan-3-yl]benzoyl]glutamic acid
-
N-[4-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexyl]benzoyl]-L-glutamic acid
-
-
N-[5-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-2-carbonyl]-L-glutamic acid
-
-
N-[5-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
-
-
N-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexanoyl]-L-glutamic acid
N-[7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanoyl]-D-glutamic acid
-
-
N-[7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanoyl]-L-glutamic acid
N-[8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanoyl]-D-glutamic acid
-
-
N-{4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl}-L-glutamic acid
-
-
N-{4-[5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)pentyl]benzoyl}-L-glutamic acid
-
-
N-{4-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexyl]benzoyl}-L-glutamic acid
-
-
N10-(Bromoacetyl)-5,8-dideazafolate
-
-
N10-formyl-2,4-diaminodideazafolate
-
-
(6R)-dideazatetrahydrofolate diglutamate
-
LY235340
(6R)-dideazatetrahydrofolate diglutamate
-
LY235340
(6R)-dideazatetrahydrofolate pentaglutamate
-
LY235542
(6R)-dideazatetrahydrofolate pentaglutamate
-
LY235542
(6R)-dideazatetrahydrofolate tetraglutamate
-
LY266978
(6R)-dideazatetrahydrofolate tetraglutamate
-
LY266978
(6R)-dideazatetrahydrofolate triglutamate
-
LY235337
(6R)-dideazatetrahydrofolate triglutamate
-
LY235337
(6S)-dideazatetrahydrofolate
-
LY243246
(6S)-dideazatetrahydrofolate
-
LY243246
10-Acetyl-5,8-dideazafolate
-
-
10-Acetyl-5,8-dideazafolate
-
-
10-Acetyl-5,8-dideazafolate
-
-
10-trifluoroacetyl-DDACTHF
-
-
10-trifluoroacetyl-DDACTHF
-
-
2',5'-furan-dideazatetrahydrofolate
-
LY222306
2',5'-furan-dideazatetrahydrofolate
-
LY222306
2',5'-thiophene dideazatetrahydrofolate
-
LY309887, diastereomer B
2',5'-thiophene dideazatetrahydrofolate
-
LY309886, diastereomer A; LY309887, diastereomer B
2',5'-thiophene dideazatetrahydrofolate
-
LY309887, diastereomer B
2',5'-thiophene dideazatetrahydrofolate
-
LY309886, diastereomer A; LY309887, diastereomer B
4-carbamoyl-2-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid
-
-
4-carbamoyl-2-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid
-
-
4-carbamoyl-4-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid
-
-
4-carbamoyl-4-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid
-
-
5,10-dideaza-5,6,7,8-tetrahydrofolate
-
-
5,10-dideaza-5,6,7,8-tetrahydrofolate
-
-
5,10-dideazatetrahydrofolate
-
-
5,10-dideazatetrahydrofolate
-
-
5,10-dideazatetrahydrofolate
-
-
DDACTHF
-
-
lometrexol
i.e. (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid
lometrexol
i.e. 5,10-dideaza-5,6,7,8-tetrahydrofolate
lometrexol
-
i.e. dideazatetrahydrofolate, specific inhibitor
N-(4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-propyl]benzoyl)-L-glutamic acid
-
dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase, resulting in potent growth inhibition of human tumor cells KB and IGROV1 that express folate receptors
N-(4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-propyl]benzoyl)-L-glutamic acid
-
dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase
N-(4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-butyl]benzoyl)-L-glutamic acid
-
dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase, resulting in potent growth inhibition of human tumor cells KB and IGROV1 that express folate receptors
N-(4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-butyl]benzoyl)-L-glutamic acid
-
dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase
N-(4-[5-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-pentyl]benzoyl)-L-glutamic acid
-
dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase, resulting in potent growth inhibition of human tumor cells KB and IGROV1 that express folate receptors
N-(4-[5-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-pentyl]benzoyl)-L-glutamic acid
-
dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase
N-(4-[6-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-hexyl]benzoyl)-L-glutamic acid
-
dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase, resulting in potent growth inhibition of human tumor cells KB and IGROV1 that express folate receptors
N-(4-[6-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-hexyl]benzoyl)-L-glutamic acid
-
dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, 5-amino-4-imidazole carboxamide ribonucleotide formyltransferase
N-([4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]phenyl]carbonyl)glutamic acid
-
-
N-([4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]phenyl]carbonyl)glutamic acid
-
-
N-([4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]phenyl]carbonyl)glutamic acid
-
-
N-([4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]phenyl]carbonyl)glutamic acid
-
-
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
-
-
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
-
-
N-[4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)propyl]benzoyl]-L-glutamic acid
-
N-[4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)propyl]benzoyl]-L-glutamic acid
-
-
N-[4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
-
N-[4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
-
-
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
-
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
-
-
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
-
-
N-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexanoyl]-L-glutamic acid
-
N-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexanoyl]-L-glutamic acid
-
-
N-[7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanoyl]-L-glutamic acid
-
N-[7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanoyl]-L-glutamic acid
-
-
pemetrexed
-
-
additional information
-
10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF and 10-methylthio-DDACTHF shows KI-values above 0.1 mM
-
additional information
-
no inhibition by N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid
-
additional information
inhibitor design and evalutaion of cofactor analogues, C10 substitution and stereochemistry, pteridine-binding pocket structure and ligand binding, modeling, overview
-
additional information
-
inhibitor design and evalutaion of cofactor analogues, C10 substitution and stereochemistry, pteridine-binding pocket structure and ligand binding, modeling, overview
-
additional information
synthesis and antitumor activity of a series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis, docking study and molecular modeling using the enzyme's crystal structure in complex with compound 10-CF3CO-DDACTHF, PDB ID 1NJS. Growth inhibition of human cancer cells by the inhibitors, IC50 values, overview
-
additional information
synthesis of 5-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors that acts as a dual inhibitor of GARFTase and AICARFTase, EC 2.1.2.3, principal mechanism of action, overview. 8, with a 4-carbon bridge, is the most active analog and potently inhibits proliferation of folate receptor alpha-expressing Chinese hamster ovary and KB human tumor cells. Molecular modeling and docking studies, overview
-
additional information
-
synthesis of 5-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors that acts as a dual inhibitor of GARFTase and AICARFTase, EC 2.1.2.3, principal mechanism of action, overview. 8, with a 4-carbon bridge, is the most active analog and potently inhibits proliferation of folate receptor alpha-expressing Chinese hamster ovary and KB human tumor cells. Molecular modeling and docking studies, overview
-
additional information
design and synthesis of series of 6-substituted straight side chain pyrrolo[2,3-d]pyrimidines with varying chain lengths (n = 5-8), non-benzoyl 6-carbon chain pyrrolo[2,3-d]pyrimidine antifolates are inhibitors of cell proliferation, correlating with expression of folate receptors. The compounds show selective cellular uptake via folate receptor-alpha and -beta, associated with high affinity binding and inhibition of de novo purine nucleotide biosynthesis via the enzyme, resulting in potent inhibition against folate receptor-expressing Chinese hamster cells and human KB tumor cells in culture
-
additional information
-
design and synthesis of series of 6-substituted straight side chain pyrrolo[2,3-d]pyrimidines with varying chain lengths (n = 5-8), non-benzoyl 6-carbon chain pyrrolo[2,3-d]pyrimidine antifolates are inhibitors of cell proliferation, correlating with expression of folate receptors. The compounds show selective cellular uptake via folate receptor-alpha and -beta, associated with high affinity binding and inhibition of de novo purine nucleotide biosynthesis via the enzyme, resulting in potent inhibition against folate receptor-expressing Chinese hamster cells and human KB tumor cells in culture
-
additional information
design and synthesis of a series of 5-substituted thiopheneyl pyrrolo[2,3-d]pyrimidines with varying chain lengths (n = 1-6). The compounds show dual inhibition of both glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase, analysis of the unique structure-activity relationship for transport and dual target inhibition, molecular modeling and computational studies using crystal structure of human GARFTase at 1.60 A resolution, PDB ID 4EW2, overview
-
additional information
-
design and synthesis of a series of 5-substituted thiopheneyl pyrrolo[2,3-d]pyrimidines with varying chain lengths (n = 1-6). The compounds show dual inhibition of both glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase, analysis of the unique structure-activity relationship for transport and dual target inhibition, molecular modeling and computational studies using crystal structure of human GARFTase at 1.60 A resolution, PDB ID 4EW2, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Cellular Pharmacodynamics of a Novel Pyrrolo[3,2-d]pyrimidine Inhibitor Targeting Mitochondrial and Cytosolic One-Carbon Metabolism.
Adenocarcinoma
Efficient experimental design and nonparametric modeling of drug interaction.
Amyotrophic Lateral Sclerosis
The glycinamide ribonucleotide transformylase (GART) gene is not responsible for familial amyotrophic lateral sclerosis.
Anemia, Megaloblastic
Role of folate dependent transformylases in synthesis of purine in bone marrow of man and in bone marrow and liver of rats.
Arthritis, Experimental
Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis.
Arthritis, Experimental
LY309887, antifolate via the folate receptor suppresses murine type II collagen-induced arthritis.
Arthritis, Rheumatoid
Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis.
Arthritis, Rheumatoid
Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs.
Breast Neoplasms
Pemetrexed: translational research in breast cancer.
Breast Neoplasms
Translational research with pemetrexed in breast cancer.
Carcinoma
A defect in the p53 response pathway induced by de novo purine synthesis inhibition.
Carcinoma
Derivation and characterization of a monoclonal antibody against human glycinamide ribonucleotide formyltransferase.
Carcinoma
Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete growth inhibition but not regression.
Carcinoma
MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
Carcinoma
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Carcinoma, Hepatocellular
Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Carcinoma, Hepatocellular
Increased expression of glycinamide ribonucleotide transformylase is associated with a poor prognosis in hepatocellular carcinoma, and it promotes liver cancer cell proliferation.
Carcinoma, Hepatocellular
Isolation and characterization of cDNA clones for rat liver 10-formyltetrahydrofolate dehydrogenase.
Carcinoma, Non-Small-Cell Lung
Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Derivation and characterization of a monoclonal antibody against human glycinamide ribonucleotide formyltransferase.
Colonic Neoplasms
Derivation and characterization of a monoclonal antibody against human glycinamide ribonucleotide formyltransferase.
Colonic Neoplasms
Improved synthetic routes to 5,8-dideazapteroylglutamates amenable to the formation of poly-gamma-L-glutamyl derivatives.
Glioma
Glycinamide ribonucleotide formyl transferase is frequently overexpressed in glioma and critically regulates the proliferation of glioma cells.
Head and Neck Neoplasms
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Infections
Novel nonclassical inhibitors of glycinamide ribonucleotide formyltransferase: 10-formyl and 10-hydroxymethyl derivatives of 5,8,10-trideazapteroic acid.
Leukemia
Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Leukemia
Biological and structural evaluation of 10R- and 10S-methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase.
Leukemia
Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Leukemia
Evidence for a relationship between intracellular GTP levels and the induction of HL-60 leukemia cell differentiation by 5,10-dideazatetrahydrofolic acid (DDATHF).
Leukemia
Folate analogues. 31. Synthesis of the reduced derivatives of 11-deazahomofolic acid, 10-methyl-11-deazahomofolic acid, and their evaluation as inhibitors of glycinamide ribonucleotide formyltransferase.
Leukemia
Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
Leukemia
Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
Leukemia
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Leukemia, Lymphoid
Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis.
Liver Neoplasms
Increased expression of glycinamide ribonucleotide transformylase is associated with a poor prognosis in hepatocellular carcinoma, and it promotes liver cancer cell proliferation.
Lung Neoplasms
Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Lymphoma
5,10-Methylenetetrahydro-5-deazafolic acid and analogues: synthesis and biological activities.
Lymphoma
Inhibition of glycinamide ribonucleotide formyltransferase and other folate enzymes by homofolate polyglutamates in human lymphoma and murine leukemia cell extracts.
Lymphoma
Mammalian glycinamide ribonucleotide transformylase: purification and some properties.
Lymphoma
Synthesis of 10-acetyl-5,8-dideazafolic acid: a potent inhibitor of glycinamide ribonucleotide transformylase.
Mesothelioma
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Mesothelioma, Malignant
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Neoplasms
5,10-Methenyltetrahydrofolate synthetase activity is increased in tumors and modifies the efficacy of antipurine LY309887.
Neoplasms
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
Neoplasms
Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol.
Neoplasms
Contributions of protein structure-based drug design to cancer chemotherapy.
Neoplasms
Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
Neoplasms
Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors.
Neoplasms
Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete growth inhibition but not regression.
Neoplasms
Enhancement of antineoplastic activity of 5-fluorouracil in mice bearing colon 38 tumor by (6R)5,10-dideazatetrahydrofolic acid.
Neoplasms
Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines.
Neoplasms
Genotoxicity of pemetrexed in human peripheral blood lymphocytes.
Neoplasms
Human glycinamide ribonucleotide transformylase: active site mutants as mechanistic probes.
Neoplasms
Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
Neoplasms
MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
Neoplasms
Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
Neoplasms
pH Effects and Cooperativity among Key Titratable Residues for Escherichia coli Glycinamide Ribonucleotide Transformylase.
Neoplasms
Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034.
Neoplasms
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
Neoplasms
Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid.
Neoplasms
Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors ? and ? and the proton-coupled folate transporter.
Neoplasms
Synergy between 5,10-dideaza-5,6,7,8-tetrahydrofolic acid and methotrexate in mice bearing L1210 tumors.
Neoplasms
Synthesis and biological activity of open-chain analogues of 5,6,7,8-tetrahydrofolic acid--potential antitumor agents.
Neoplasms
The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol.
Neoplasms
Thienyl and thiazolyl acyclic analogues of 5-deazatetrahydrofolic acid.
Neoplasms
Translational research with pemetrexed in breast cancer.
Neoplasms
TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Neoplasms
Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor ? and inhibition of de novo purine nucleotide biosynthesis.
Neoplasms
Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet.
Neuroblastoma
5,10-Methenyltetrahydrofolate synthetase activity is increased in tumors and modifies the efficacy of antipurine LY309887.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis.
Tuberculosis
Structures of Glycinamide Ribonucleotide Transformylase (PurN) from Mycobacterium tuberculosis Reveal a Novel Dimer with Relevance to Drug Discovery.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0775 - 0.0848
(6R)-N10-formyltetrahydrofolate
0.000075 - 33
10-formyl-5,8-dideazafolate
0.019
5,8-Dideazafolate
-
-
0.00368
acetate
-
purT gene product
0.0774
ATP
-
purT gene product
0.0011 - 33
beta-glycinamide ribonucleotide
0.0036 - 0.0465
carbocyclic beta-glycinamide ribonucleotide
0.018
carbocyclic glycinamide ribonucleotide
-
-
0.319
formate
-
purT gene product
0.102
formyl-beta-glycinamide ribonucleotide
-
-
0.01 - 0.4
glycinamide ribonucleotide
0.052
glycinamide ribotide
-
-
0.00576
L-(+)-5,10-methenyltetrahydrofolate
-
-
0.0008 - 0.00676
L-(-)-10-formyltetrahydrofolate
0.21
N-formylglycinamide ribotide
-
-
0.0211 - 0.099
N10-formyl-5,8-dideazafolate
0.19
N10-formyl-5-deazafolate
-
-
0.15
N10-Formyl-8-deazafolate
-
-
0.0167 - 0.0365
N10-formyldideazafolate
0.058
N5,N10-anhydroformyl tetrahydrofolate
-
-
0.0775
(6R)-N10-formyltetrahydrofolate
-
pH 8.5
0.0848
(6R)-N10-formyltetrahydrofolate
-
pH 7.5
0.000075
10-formyl-5,8-dideazafolate
-
recombinant enzyme
0.00025
10-formyl-5,8-dideazafolate
-
-
0.0009
10-formyl-5,8-dideazafolate
-
wild type enzyme
0.0013
10-formyl-5,8-dideazafolate
-
-
0.0015
10-formyl-5,8-dideazafolate
-
recombinant enzyme, expressed in E.coli
0.0015
10-formyl-5,8-dideazafolate
-
mutant K170R
0.0019
10-formyl-5,8-dideazafolate
-
-
0.01
10-formyl-5,8-dideazafolate
-
mutant H108A
0.0123
10-formyl-5,8-dideazafolate
-
-
0.0123
10-formyl-5,8-dideazafolate
-
wild-type
0.017
10-formyl-5,8-dideazafolate
-
-
0.0196
10-formyl-5,8-dideazafolate
-
mutant N106Q
0.024
10-formyl-5,8-dideazafolate
-
mutant H108Q
0.025
10-formyl-5,8-dideazafolate
-
mutant D144A
0.035
10-formyl-5,8-dideazafolate
-
purN/purU hybrid enzyme
0.128
10-formyl-5,8-dideazafolate
-
mutant 13N + 13C 1:1
0.131
10-formyl-5,8-dideazafolate
-
mutant B13
0.9
10-formyl-5,8-dideazafolate
-
mutant N106G
0.99
10-formyl-5,8-dideazafolate
-
chimeric enzyme GPG-N11 (hGART1-56/PurN57-131/hGART132-202)
4
10-formyl-5,8-dideazafolate
-
wild-type enzyme
4
10-formyl-5,8-dideazafolate
-
chimeric enzyme GPX-M1 (hGART1-100/PurN101-212)
12
10-formyl-5,8-dideazafolate
-
chimeric enzyme GPX-M55 (hGART1-56/PurN58-212)
21
10-formyl-5,8-dideazafolate
-
chimeric enzyme GPX-M24 (hGART1-54/PurN55-212)
33
10-formyl-5,8-dideazafolate
-
chimeric enzyme PGX-B12 (PurN1-101/hGART102-202)
0.0011
beta-glycinamide ribonucleotide
-
-
0.0011
beta-glycinamide ribonucleotide
-
wild type enzyme
0.0018
beta-glycinamide ribonucleotide
-
mutant K170R
0.008
beta-glycinamide ribonucleotide
-
pH 8.5, tetrahydrofolate as cofactor
0.0101
beta-glycinamide ribonucleotide
-
-
0.0101
beta-glycinamide ribonucleotide
-
purT gene product
0.012
beta-glycinamide ribonucleotide
-
pH 7.5, tetrahydrofolate as cofactor
0.0122
beta-glycinamide ribonucleotide
-
pH 7.5, tetrahydrofolate as cofactor
0.016
beta-glycinamide ribonucleotide
-
purN/purU hybrid enzyme
0.018
beta-glycinamide ribonucleotide
-
mutant H108Q
0.019
beta-glycinamide ribonucleotide
-
-
0.0192
beta-glycinamide ribonucleotide
-
pH 7.5, dideazafolate as cofactor
0.0235
beta-glycinamide ribonucleotide
-
pH 8.5, dideazafolate as cofactor
0.029
beta-glycinamide ribonucleotide
-
mutant D144A
0.0295
beta-glycinamide ribonucleotide
-
mutant N106Q
0.054
beta-glycinamide ribonucleotide
-
mutant H108A
0.095
beta-glycinamide ribonucleotide
-
wild-type
0.115
beta-glycinamide ribonucleotide
-
strain H108A
0.118
beta-glycinamide ribonucleotide
-
-
0.118
beta-glycinamide ribonucleotide
-
wild-type
0.122
beta-glycinamide ribonucleotide
-
strain D144A
0.178
beta-glycinamide ribonucleotide
-
mutant B13
0.19
beta-glycinamide ribonucleotide
-
mutant 13N + 13C 1:1
0.414
beta-glycinamide ribonucleotide
-
strain H121Q
0.99
beta-glycinamide ribonucleotide
-
chimeric enzyme GPG-N11 (hGART1-56/PurN57-131/hGART132-202)
4
beta-glycinamide ribonucleotide
-
wild-type enzyme
4
beta-glycinamide ribonucleotide
-
chimeric enzyme GPX-M1 (hGART1-100/PurN101-212)
12
beta-glycinamide ribonucleotide
-
chimeric enzyme GPX-M55 (hGART1-56/PurN58-212)
21
beta-glycinamide ribonucleotide
-
chimeric enzyme GPX-M24 (hGART1-54/PurN55-212)
33
beta-glycinamide ribonucleotide
-
chimeric enzyme PGX-B12 (PurN1-101/hGART102-202)
0.0036
carbocyclic beta-glycinamide ribonucleotide
-
-
0.0369
carbocyclic beta-glycinamide ribonucleotide
-
-
0.0465
carbocyclic beta-glycinamide ribonucleotide
-
-
0.01
glycinamide ribonucleotide
-
-
0.4
glycinamide ribonucleotide
-
-
0.0008
L-(-)-10-formyltetrahydrofolate
-
-
0.00594
L-(-)-10-formyltetrahydrofolate
-
in absence of trifunctional protein
0.00676
L-(-)-10-formyltetrahydrofolate
-
-
0.0211
N10-formyl-5,8-dideazafolate
-
wild-type
0.0211
N10-formyl-5,8-dideazafolate
-
strain H108A
0.0284
N10-formyl-5,8-dideazafolate
-
strain D144A
0.099
N10-formyl-5,8-dideazafolate
-
strain H121Q
0.0167
N10-formyldideazafolate
-
pH 7.5
0.0365
N10-formyldideazafolate
-
pH 8.5
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00021
(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid
-
-
0.0014
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid
-
-
0.0012
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid
-
-
0.0011
(S)-2-(4-(2-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl)-1,3-dithian-2-yl)benzamido)pentanedioic acid
-
-
0.000015
10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
-
0.000015 - 0.00003
10-CF3CO-DDACTHF
0.000014
10-formyl-DDACTHF
0.00058
10-methanesulfonyl-5-DACTHF
-
26°C, pH 7.5
0.00023
10-methanesulfonyl-DDACTHF
-
26°C, pH 7.5
0.00025
10-methylthio-DDACTHF
0.000015 - 0.0019
10-trifluoroacetyl-DDACTHF
0.0067
2,4-diamino-6-(3,4,5-trimethoxyanilino)-methylpyrido[3,2-d]pyrimidine
pH and temperature not specified in the publication
0.02754
2,4-diamino-6-(3,4,5-trimethoxybenzyl)-5,6,7,8-tetrahydro-quinazoline
pH and temperature not specified in the publication
0.000056
4-carbamoyl-2-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid
-
26°C, pH 7.5
0.0048
4-carbamoyl-4-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid
-
26°C, pH 7.5
0.04218
5-((4-carboxy-4-(4-(((2,4-diaminopyrido[3,2-d]pyrimidine-6-yl)methyl)amino)benzamido)butyl)carbamoyl)-isophthalic acid
pH and temperature not specified in the publication
0.0093
LY231514 monoglutamate
-
-
0.000065
LY231514 pentaglutamate
-
-
0.0011
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid
-
-
0.00085
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid
-
-
0.00018
N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid
-
-
0.000005 - 0.00005
N-[(5-[2-[(6R)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophen-2-yl)carbonyl]glutamic acid
pH and temperature not specified in the publication
0.000005 - 0.00005
N-[(5-[2-[(6R)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl]thiophen-2-yl)carbonyl]glutamic acid
pH and temperature not specified in the publication
0.000005 - 0.00005
N-[(5-[2-[(6S)-2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]thiophen-2-yl)carbonyl]glutamic acid
pH and temperature not specified in the publication
0.00021
N-[4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]benzoyl]glutamic acid
pH and temperature not specified in the publication
0.00018
N-[4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]benzoyl]glutamic acid
pH and temperature not specified in the publication
0.00006
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
-
-
0.001067
N-[4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
-
at pH 7.5 and 37°C
0.000017
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
-
at pH 7.5 and 37°C
0.000007 - 0.000009
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
0.0005
N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid
-
26°C, pH 7.5
0.000068
N-[5-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-2-carbonyl]-L-glutamic acid
-
at pH 7.5 and 37°C
0.000022
N-[5-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
-
at pH 7.5 and 37°C
0.000067
N-[7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanoyl]-D-glutamic acid
-
at pH 7.5 and 37°C
0.000099
N-[8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanoyl]-D-glutamic acid
-
at pH 7.5 and 37°C
additional information
additional information
-
4-carbamoyl-2-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid and 4-carbamoyl-4-[4-[4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(2,2,2-trifluoroacetyl)butyl]benzoylamino]butyric acid show Ki-values above 0.1 mM
-
0.000015
10-CF3CO-DDACTHF
-
-
0.000015
10-CF3CO-DDACTHF
-
26°C, pH 7.5
0.00003
10-CF3CO-DDACTHF
-
-
0.000014
10-formyl-DDACTHF
-
-
0.000014
10-formyl-DDACTHF
-
26°C, pH 7.5
0.00025
10-methylthio-DDACTHF
-
-
0.00025
10-methylthio-DDACTHF
-
26°C, pH 7.5
0.000015
10-trifluoroacetyl-DDACTHF
-
26°C, pH 7.5
0.0019
10-trifluoroacetyl-DDACTHF
-
26°C, pH 7.5
0.0017
DDACTHF
-
-
0.0017
DDACTHF
-
26°C, pH 7.5
0.005
DDACTHF
-
26°C, pH 7.5
0.000007
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
-
at pH 7.5 and 37°C
0.000009
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
-
at pH 7.5 and 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00007 - 0.01
(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid
0.0005 - 0.01
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid
0.0007 - 0.01
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid
0.01 - 0.1
(S)-2-(4-(2-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl)-1,3-dithian-2-yl)benzamido)pentanedioic acid
0.000016 - 0.01
10-CF3CO-DDACTHF
0.00852
N-(4-[3-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-propyl]benzoyl)-L-glutamic acid
Mus musculus
-
pH 7.5, 37°C
0.00551
N-(4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-butyl]benzoyl)-L-glutamic acid
Mus musculus
-
pH 7.5, 37°C
0.0024 - 0.01
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid
0.0005 - 0.01
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid
0.00005 - 0.01
N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid
0.001 - 0.02
N-([4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]phenyl]carbonyl)glutamic acid
0.000018 - 0.00244
N-([4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]phenyl]carbonyl)glutamic acid
0.000014 - 0.1
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
0.0000049
N-[4-[4-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
Homo sapiens
-
at pH 7.5 and 37°C
0.0000019 - 0.00015
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
0.00000017 - 0.00000027
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
0.0000072 - 0.00226
N-[4-[5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)pentyl]benzoyl]-L-glutamic acid
0.0000086 - 0.00251
N-[4-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexyl]benzoyl]-L-glutamic acid
0.00000026
N-[5-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophene-2-carbonyl]-L-glutamic acid
Homo sapiens
-
at pH 7.5 and 37°C
0.00000055
N-[5-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
Homo sapiens
-
at pH 7.5 and 37°C
0.0000079
N-[7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanoyl]-D-glutamic acid
Homo sapiens
-
at pH 7.5 and 37°C
0.0000011
N-[8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanoyl]-D-glutamic acid
Homo sapiens
-
at pH 7.5 and 37°C
0.00003 - 0.02
pemetrexed
additional information
N-(4-[5-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-pentyl]benzoyl)-L-glutamic acid
0.00007
(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/MTX cell, in the absence of thymidine, in the absence of hypoxanthine
0.00008
(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.00008
(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.00009
(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0055
(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/FPGS- cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
(S)-2-(((4R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylthio)butyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.0005
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0006
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0006
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/MTX cell, in the absence of thymidine, in the absence of hypoxanthine
0.0006
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.01
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/FPGS- cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.0007
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0008
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0009
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/MTX cell, in the absence of thymidine, in the absence of hypoxanthine
0.0009
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.01
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/FPGS- cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
(S)-2-(4((S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.01
(S)-2-(4-(2-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl)-1,3-dithian-2-yl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.1
(S)-2-(4-(2-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl)-1,3-dithian-2-yl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.1
(S)-2-(4-(2-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl)-1,3-dithian-2-yl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.1
(S)-2-(4-(2-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)propyl)-1,3-dithian-2-yl)benzamido)pentanedioic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.000016
10-CF3CO-DDACTHF
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.000017
10-CF3CO-DDACTHF
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.00006
10-CF3CO-DDACTHF
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
10-CF3CO-DDACTHF
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/FPGS- cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
10-CF3CO-DDACTHF
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.0027
DDACTHF
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0027
DDACTHF
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0036
DDACTHF
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.01
DDACTHF
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/FPGS- cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
DDACTHF
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.1
DDACTHF
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/MTX cell, in the absence of thymidine, in the absence of hypoxanthine
0.0024
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0044
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/MTX cell, in the absence of thymidine, in the absence of hypoxanthine
0.0055
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0057
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.01
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/FPGS- cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-hydroxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.0005
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0006
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0006
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/MTX cell, in the absence of thymidine, in the absence of hypoxanthine
0.0007
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.006
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/FPGS- cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
N-([4-[(1R)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-methoxybutyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.00005
N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.00006
N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.00006
N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/MTX cell, in the absence of thymidine, in the absence of hypoxanthine
0.00007
N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.005
N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/FPGS- cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
N-([4-[(1S)-4-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-1-(methylsulfanyl)butyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.001
N-([4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in situ
0.02
N-([4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]phenyl]carbonyl)glutamic acid
Mus musculus
-
in vitro
0.000018
N-([4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]phenyl]carbonyl)glutamic acid
Homo sapiens
-
in situ
0.00244
N-([4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]phenyl]carbonyl)glutamic acid
Mus musculus
-
in vitro
0.000014
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in situ
0.0002
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0002
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the absence of hypoxanthine
0.0002
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the presence of thymidine, in the absence of hypoxanthine
0.00078
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
Mus musculus
-
in vitro
0.01
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/FPGS- cell, in the absence of thymidine, in the absence of hypoxanthine
0.01
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in vitro cytotoxic activity, CCRF-CEM cell, in the absence of thymidine, in the presence of hypoxanthine
0.1
N-[4-[2-[(6R)-2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in vitro cytotoxic activity in mutant cell line, CCRF-CEM/MTX cell, in the absence of thymidine, in the absence of hypoxanthine
0.0000019
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
Homo sapiens
-
at pH 7.5 and 37°C
0.0000068
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in situ
0.00015
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]benzoyl]-L-glutamic acid
Mus musculus
-
in vitro
0.00000017
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
Homo sapiens
-
at pH 7.5 and 37°C
0.00000027
N-[4-[4-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophene-2-carbonyl]-L-glutamic acid
Homo sapiens
-
at pH 7.5 and 37°C
0.0000072
N-[4-[5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)pentyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in situ
0.00226
N-[4-[5-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)pentyl]benzoyl]-L-glutamic acid
Mus musculus
-
in vitro
0.0000086
N-[4-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexyl]benzoyl]-L-glutamic acid
Homo sapiens
-
in situ
0.00251
N-[4-[6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexyl]benzoyl]-L-glutamic acid
Mus musculus
-
in vitro
0.00003
pemetrexed
Homo sapiens
-
in situ
0.02
pemetrexed
Mus musculus
-
in vitro
additional information
N-(4-[5-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-pentyl]benzoyl)-L-glutamic acid
Mus musculus
-
IC50 value above 0.02 mM, pH 7.5, 37°C
additional information
N-(4-[6-(2-amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-hexyl]benzoyl)-L-glutamic acid
Mus musculus
-
IC50 value above 0.02 mM, pH 7.5, 37°C
additional information
N-(4-[[(2,4-diaminopteridin-6-yl)methyl](methyl)amino]benzoyl)glutamic acid
Homo sapiens
-
value above 0.05
additional information
N-([5-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2,3-dihydrothiophen-2-yl]carbonyl)-4-methylideneglutamic acid
Homo sapiens
-
value above 0.05
additional information
N-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-4-methylideneglutamic acid
Homo sapiens
-
value above 0.05
additional information
N-[4-[2-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
Homo sapiens
-
value above 0.05
additional information
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]-2-fluorobenzoyl]-4-methylideneglutamic acid
Homo sapiens
-
value above 0.05
additional information
N-[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
Homo sapiens
-
value above 0.05
additional information
N-[4-[2-(2-amino-4-methylquinazolin-6-yl)ethyl]benzoyl]-4-methylideneglutamic acid
Homo sapiens
-
value above 0.05
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Daubner, S.C.; Schrimsher, J.L.; Schendel, F.J.; Young, M.; Henikoff, S.; Patterson, D.; Stubbe, J.; Benkovic, S.J.
A multifunctional protein possessing glycinamide ribonucleotide synthetase, glycinamide ribonucleotide transformylase, and aminoimidazole ribonucleotide synthetase activities in de novo purine biosynthesis
Biochemistry
24
7059-7062
1985
Saccharomyces cerevisiae, Gallus gallus, Drosophila melanogaster, Schizosaccharomyces pombe
brenda
Caperelli, C.A.; Liu, D.
Carbocyclic substrates for de novo purine biosynthesis. Enantiospecific synthesis and enantiospecificity of enzymatic utilization
J. Biol. Chem.
267
9783-9787
1992
Homo sapiens, Mus musculus
brenda
Caperelli, C.A.; Benkovic, P.A.; Chettur, G.; Benkovic, S.J
Purification of a complex catalizing folate cofactor synthesis and transformylation in de novo purine biosynthesis
J. Biol. Chem.
255
1885-1890
1980
Saccharomyces cerevisiae, Gallus gallus, Columba sp., Oryctolagus cuniculus, Ovis aries, Sus scrofa
brenda
Hards, R.G.; Graw, S.L.; Patterson, D.
Purification of mammalian glycinamide ribonucleotide (GAR) synthetase
Adv. Exp. Med. Biol.
195
315-319
1986
Rattus norvegicus
-
brenda
Caperelli, C.A.; Chettur, G.; Lin-Kosley, L.
Purification of glycineamide ribonucleotide transformylase
Dev. Biochem.
4
371-376
1979
Gallus gallus
-
brenda
Warren, L.; Buchanan, J.M.
Biosynthesis of the purines. XIX. 2-Amino-N-ribosylacetamide 5'-phosphate(glycinamide ribotide) transformylase
J. Biol. Chem.
229
613-626
1957
Gallus gallus, Clostridium cylindrosporum, Columba sp.
brenda
Smith, G.K.; Benkovic, P.A.; Benkovic, S.J.
L(-)-10-formyltetrahydrofolate is the cofactor for glycinamide ribonucleotide transformylase from chicken liver
Biochemistry
20
4034-4036
1981
Gallus gallus, Escherichia coli
brenda
Chen, P.; Schulze-Gahmen, U.; Stura, E.A.; Inglese, J.; Johnson, D.L.; Marolewski, A.; Benkovic, S.J.; Wilson, I.A.
Crystal structure of glycinamide ribonucleotide transformylase from Escherichia coli at 3.0 A resolution
J. Mol. Biol.
227
283-292
1992
Bacillus subtilis, Saccharomyces cerevisiae, Drosophila melanogaster, Escherichia coli, Homo sapiens, Mus musculus
brenda
Caperelli, C.A.; Chettur, G.; Lin, L.Y.; Benkovic, S.J.
Purification of glycineamide ribonucleotide transformylase
Biochem. Biophys. Res. Commun.
82
403-410
1978
Saccharomyces cerevisiae, Gallus gallus, Ovis aries, Sus scrofa
brenda
Caperelli, C.A.; Price, M.F.
Carbocyclic glycinamide ribonucleotide is a substrate for glycinamide ribonucleotide transformylase
Arch. Biochem. Biophys.
264
340-342
1988
Mus musculus
brenda
Inglese, J.; Johnson, D.L.; Shiau, A.; Smith, J.M.; Benkovic, S.J.
Subcloning, characterization, and affinity labeling of Escherichia coli glycinamide ribonucleotide transformylase
Biochemistry
29
1436-1443
1990
Bacillus subtilis, Cricetulus griseus, Drosophila melanogaster, Escherichia coli, Gallus gallus, Homo sapiens, Mus musculus, Saccharomyces cerevisiae
brenda
Almassy, R.J.; Janson, C.A.; Kann, C.C.; Hostomska, Z.
Structures of apo and complexed Escherichia coli glycinamide ribonucleotide transformylase
Proc. Natl. Acad. Sci. USA
89
6114-6118
1992
Escherichia coli, Mus musculus
brenda
Stura, E.A.; Johnson, D.L; Inglese, J.; Smith, J.M.; Benkovic, S.J.; Wilson, I.A.
Preliminary crystallographic investigations of glycinamide ribonucleotide transformylase
J. Biol. Chem.
264
9703-9706
1989
Escherichia coli
brenda
Young, M.; Sammons, R.D.; Mueller, W.T.; Benkovic, S.J.
An antibody probe to determine the native species of glycinamide ribonucleotide transformylase in chicken liver
Biochemistry
23
3979-3986
1984
Gallus gallus, Mus musculus
brenda
Caperelli, C.A.
Mammalian glycinamide ribonucleotide transformylase: Purification and some properties
Biochemistry
24
1316-1320
1985
Gallus gallus, Mus musculus
brenda
Caperelli, C.A.
Mammalian glycinamide ribonucleotide transformylase. Kinetic mechanism and associated de novo purine biosynthesis activities
J. Biol. Chem.
264
5053-5057
1989
Gallus gallus, Drosophila melanogaster, Homo sapiens, Mus musculus
brenda
Dev, I.K.; Harvey, R.J.
N10-Formyltetrahydrofolate is the formyl donor for glycinamide ribonucleotide transformylase in Escherichia coli
J. Biol. Chem.
253
4242-4244
1978
Escherichia coli, Escherichia coli B / ATCC 11303, Gallus gallus, Salmonella enterica subsp. enterica serovar Typhimurium
brenda
Smith, G.K.; Mueller, W.T.; Wasserman, G.F.; Taylor, W.D.; Benkovic, S.J.
Characterization of the enzyme complex involving the folate-requiring enzymes of de novo purine biosynthesis
Biochemistry
19
4313-4321
1980
Gallus gallus, Escherichia coli
brenda
Warren, M.S.; Marolewski, A.E.; Benkovic, S.J.
A rapid screen of active site mutants in glycinamide ribonucleotide transformylase
Biochemistry
35
8855-8862
1996
Bacillus subtilis, Saccharomyces cerevisiae, Gallus gallus, Drosophila melanogaster, Escherichia coli, Homo sapiens
brenda
Liu, C.; Shim, J.H.; Benkovic, S.J.
The unexpected catalytic properties of a heterodimer of GAR transformylase
Bioorg. Chem.
28
316-323
2000
Escherichia coli
brenda
Sanghani, S.P.; Moran, R.G.
Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase
Biochemistry
36
10506-10516
1997
Gallus gallus, Escherichia coli, Homo sapiens, Mus musculus
brenda
Marolewski, A.; Smith, J.M.; Benkovic, S.J.
Cloning and characterization of a new purine biosynthetic enzyme: a non-folate glycinamide ribonucleotide transformylase from E. coli
Biochemistry
33
2531-2537
1994
Escherichia coli, Escherichia coli TX635
brenda
Nixon, A.E.; Benkovic, S.J.
Improvement in the efficiency of formyl transfer of a GAR transformylase hybrid enzyme
Protein Eng.
13
323-327
2000
Escherichia coli
brenda
Caperelli, C.A.; Giroux, E.L.
The human glycinamide ribonucleotide transformylase domain: purification, characterization, and kinetic mechanism
Arch. Biochem. Biophys.
341
98-103
1997
Bacillus subtilis, Saccharomyces cerevisiae, Gallus gallus, Escherichia coli, Homo sapiens
brenda
Antle, V.D.; Donat, N.; Hua, M.; Liao, P.L.; Vince, R.; Caperelli, C.A.
Substrate specificity of human glycinamide ribonucleotide transformylase
Arch. Biochem. Biophys.
370
231-235
1999
Gallus gallus, Escherichia coli, Homo sapiens
brenda
McMorran, B.J.; Kumara, H.M.C.S.; Sullivan, K.; Lamont, I.L.
Involvement of a transformylase enzyme in siderophore synthesis in Pseudomonas aeruginosa
Microbiology
147
1517-1524
2001
Arabidopsis thaliana, Bacillus subtilis, Saccharomyces cerevisiae, Drosophila melanogaster, Escherichia coli, Pseudomonas aeruginosa
brenda
Habeck, L.L.; Leitner, T.A.; Shackelford, K.A.; Gossett, L.S.; Schultz, R.M.; Andis, S.L.; Shih, C.; Grindey, G.B.; Mendelsohn, L.G.
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors
Cancer Res.
54
1021-1026
1994
Homo sapiens, Mus musculus
brenda
Antle, V.D.; Liu, D.; McKellar, B.R.; Caperelli, C.A.; Hua, M.; Vince, R.
Substrate specificity of glycinamide ribonucleotide transformylase from chicken liver
J. Biol. Chem.
271
6045-6049
1996
Gallus gallus, Escherichia coli
brenda
Shim, J.H.; Benkovic, S.J.
Evaluation of the kinetic mechanism of Escherichia coli glycinamide ribonucleotide transformylase
Biochemistry
37
8776-8782
1998
Escherichia coli, Homo sapiens, Mus musculus
brenda
Gooljarsingh, L.T.; Ramcharan, J.; Gilroy, S.; Benkovic, S.J.
Localization of GAR transformylase in Escherichia coli and mammalian cells
Proc. Natl. Acad. Sci. USA
98
6565-6570
2001
Escherichia coli, Homo sapiens
brenda
Shim, J.H.; Benkovic, S.J.
Evaluation of the kinetic mechanism of Escherichia coli glycinamide ribonucleotide transformylase probed by site-directed mutagenesis and pH-dependent studies
Biochemistry
38
10024-10031
1999
Escherichia coli
brenda
Hartman, S.C.; Buchanan, J.M.
Biosynthesis of the purines. XXVI. The Identification of the formyl donors of the transformylation reactions
J. Biol. Chem.
234
1812-1816
1959
Gallus gallus
brenda
Zhang, Y.; Desharnais, J.; Marsilje, T.H.; Li, C.; Hedrick, M.P.; Gooljarsingh, L.T.; Tavassoli, A.; Benkovic, S.J.; Olson, A.J.; Boger, D.L.; Wilson, I.A.
Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid
Biochemistry
42
6043-6056
2003
Homo sapiens (P22102), Homo sapiens
brenda
Shi, C.; Chen, V.J.; et.al.
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
Cancer Res.
57
1116-1123
1997
Homo sapiens
brenda
Lee, S.G.; Lutz, S.; Benkovic, S.J.
On the structural and functional modularity of glycinamide ribonucleotide formyltransferases
Protein Sci.
12
2206-2214
2003
Homo sapiens
brenda
Cheng, H.; Chong, Y.; Hwang, I.; Tavassoli, A.; Zhang, Y.; Wilson, I.A.; Benkovic, S.J.; Boger, D.L.
Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway
Bioorg. Med. Chem.
13
3577-3585
2005
Escherichia coli, Homo sapiens
brenda
Chong, Y.; Hwang, I.; Tavassoli, A.; Zhang, Y.; Wilson, I.A.; Benkovic, S.J.; Boger, D.L.
Synthesis and biological evaluation of alpha- and gamma-carboxamide derivatives of 10-CF3CO-DDACTHF
Bioorg. Med. Chem.
13
3587-3592
2005
Escherichia coli, Homo sapiens
brenda
Cheng, H.; Hwang, I.; Chong, Y.; Tavassoli, A.; Webb, M.E.; Zhang, Y.; Wilson, I.A.; Benkovic, S.J.; Boger, D.L.
Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathway
Bioorg. Med. Chem.
13
3593-3599
2005
Escherichia coli, Homo sapiens
brenda
Woehlke, A.; Droegemueller, C.; Kuiper, H.; Leeb, T.; Distl, O.
Molecular characterization and chromosomal assignment of the bovine glycinamide ribonucleotide formyltransferase (GART) gene on cattle chromosome 1q12.1-q12.2
Gene
348
73-81
2005
Bos taurus (Q599X3), Bos taurus (Q599X4), Bos taurus (Q599X5), Bos taurus
brenda
Manieri, W.; Moore, M.E.; Soellner, M.B.; Tsang, P.; Caperelli, C.A.
Human glycinamide ribonucleotide transformylase: active site mutants as mechanistic probes
Biochemistry
46
156-163
2007
Homo sapiens
brenda
Deng, Y.; Wang, Y.; Cherian, C.; Hou, Z.; Buck, S.A.; Matherly, L.H.; Gangjee, A.
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity
J. Med. Chem.
51
5052-5063
2008
Homo sapiens, Mus musculus
brenda
DeMartino, J.K.; Hwang, I.; Connelly, S.; Wilson, I.A.; Boger, D.L.
Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase
J. Med. Chem.
51
5441-5448
2008
Homo sapiens
brenda
Liang, Y.H.; Liu, X.Y.; Wang, J.; Li, L.F.
Protein preparation, crystallization and preliminary crystallographic studies of Bacillus subtilis glycinamide ribonucleotide transformylase
Acta Crystallogr. Sect. F
65
709-711
2009
Bacillus subtilis (P12040), Bacillus subtilis
brenda
McGuire, J.J.; Haile, W.H.
Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-D,L-4-methyleneglutamic acid (CH-1504) and its analogs
Biochem. Pharmacol.
77
1161-1172
2009
Homo sapiens
brenda
Deng, Y.; Zhou, X.; Kugel Desmoulin, S.; Wu, J.; Cherian, C.; Hou, Z.; Matherly, L.H.; Gangjee, A.
Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transpo
J. Med. Chem.
52
2940-2951
2009
Homo sapiens, Mus musculus
brenda
Zhang, Z.; Caradoc-Davies, T.T.; Dickson, J.M.; Baker, E.N.; Squire, C.J.
Structures of glycinamide ribonucleotide transformylase (PurN) from Mycobacterium tuberculosis reveal a novel dimer with relevance to drug discovery
J. Mol. Biol.
389
722-733
2009
Mycobacterium tuberculosis (P9WHM5), Mycobacterium tuberculosis, Mycobacterium tuberculosis H37Rv (P9WHM5)
brenda
Zhai, F.; Liu, X.; Ruan, J.; Li, J.; Liu, Z.; Hu, Y.; Li, S.
Expression, crystallization and preliminary X-ray analysis of the phosphoribosylglycinamide formyltransferase from Streptococcus mutans
Acta Crystallogr. Sect. F
67
287-290
2011
Streptococcus mutans
brenda
Connelly, S.; DeMartino, J.K.; Boger, D.L.; Wilson, I.A.
Biological and structural evaluation of 10R- and 10S-methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase
Biochemistry
52
5133-5144
2013
Homo sapiens (P22102), Homo sapiens
brenda
Liu, Y.; Zhang, C.; Zhang, H.; Li, M.; Yuan, J.; Zhang, Y.; Zhou, J.; Guo, H.; Zhao, L.; Du, Y.; Wang, L.; Ren, L.
Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis
Eur. J. Med. Chem.
93
142-155
2015
Homo sapiens (P22102)
brenda
Cong, X.; Lu, C.; Huang, X.; Yang, D.; Cui, X.; Cai, J.; Lv, L.; He, S.; Zhang, Y.; Ni, R.
Increased expression of glycinamide ribonucleotide transformylase is associated with a poor prognosis in hepatocellular carcinoma, and it promotes liver cancer cell proliferation
Hum. Pathol.
45
1370-1378
2014
Homo sapiens (P22102), Homo sapiens
brenda
Mitchell-Ryan, S.; Wang, Y.; Raghavan, S.; Ravindra, M.P.; Hales, E.; Orr, S.; Cherian, C.; Hou, Z.; Matherly, L.H.; Gangjee, A.
Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: Implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to AMPK activation and anti-tumor activity
J. Med. Chem.
56
10016-10032
2013
Homo sapiens (P22102), Homo sapiens
brenda
Wang, Y.; Cherian, C.; Orr, S.; Mitchell-Ryan, S.; Hou, Z.; Raghavan, S.; Matherly, L.H.; Gangjee, A.
Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor alpha and inhibition of de novo purine nucleotide biosynthesis
J. Med. Chem.
56
8684-8695
2013
Homo sapiens (P22102), Homo sapiens
brenda
Wang, Y.; Mitchell-Ryan, S.; Raghavan, S.; George, C.; Orr, S.; Hou, Z.; Matherly, L.H.; Gangjee, A.
Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents
J. Med. Chem.
58
1479-1493
2015
Homo sapiens (P22102), Homo sapiens
brenda
Liu, X.; Ding, Z.; Liu, Y.; Zhang, J.; Liu, F.; Wang, X.; He, X.; Cui, G.; Wang, D.
Glycinamide ribonucleotide formyl transferase is frequently overexpressed in glioma and critically regulates the proliferation of glioma cells
Pathol. Res. Pract.
210
256-263
2014
Homo sapiens (P22102)
brenda
Liu, X.; Ding, Z.; Liu, Y.; Zhang, J.; Liu, F.; Wang, X.; He, X.; Cui, G.; Wang, D.
Glycinamide ribonucleotide formyl transferase is frequently overexpressed in glioma and critically regulates the proliferation of glioma cells
Pathol. Res. Pract.
210
256-263
2014
Homo sapiens (P22102)
brenda
Deis, S.M.; Doshi, A.; Hou, Z.; Matherly, L.H.; Gangjee, A.; Dann, C.E.
Structural and enzymatic analysis of tumor-targeted antifolates that inhibit glycinamide ribonucleotide formyltransferase
Biochemistry
55
4574-4582
2016
Homo sapiens
brenda
Xing, R.; Zhang, H.; Yuan, J.; Zhang, K.; Li, L.; Guo, H.; Zhao, L.; Zhang, C.; Li, S.; Gao, T.; Liu, Y.; Wang, L.
Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase
Eur. J. Med. Chem.
139
531-541
2017
Homo sapiens
brenda
Xu, L.; Wang, L.; Wang, J.; Zhu, Z.; Chang, G.; Guo, Y.; Tian, X.; Niu, B.
The effect of inhibiting glycinamide ribonucleotide formyl transferase on the development of neural tube in mice
Nutr. Metab.
13
56
2016
Mus musculus
brenda
Batool, S.; Nawaz, M.S.; Mushtaq, G.; Parvaiz, F.; Kamal, M.A.
In silico analysis of glycinamide ribonucleotide transformylase inhibition by PY873, PY899 and DIA
Saudi J. Biol. Sci.
24
1155-1161
2017
Homo sapiens (P22102), Homo sapiens
brenda